Clinical Trials Logo
  1. Home
  2. Carcinoid Syndrome
  3. NCT00853047

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Carcinoid Syndrome Clinical Trial

Official title:
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide therapy. Following determination of the maximally tolerated or effective dose, cohort expansion will occur to confirm effect on symptoms and safety profile.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00853047
Study type Interventional
Source Lexicon Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date March 2009
Completion date June 2014
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04993261 - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors Early Phase 1
Not yet recruiting NCT04039516 - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Phase 2
Completed NCT01234168 - A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Terminated NCT04073017 - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency N/A
Recruiting NCT05756608 - Fibrosis in Chronic and Delayed Myocardial Infarction
Completed NCT00774930 - An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Phase 3
Withdrawn NCT04713202 - Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl Phase 2
Completed NCT02063659 - Telotristat Etiprate for Carcinoid Syndrome Therapy Phase 3
Withdrawn NCT04776876 - Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome Phase 2
Completed NCT03223428 - Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Recruiting NCT03453489 - AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Phase 2
Active, not recruiting NCT05361668 - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Phase 2
Completed NCT01104415 - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Phase 2
Withdrawn NCT01172717 - Study of Panitumumab in the Treatment of Carcinoid Syndrome Phase 2
Terminated NCT00884715 - Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome Phase 1/Phase 2
Completed NCT01677910 - TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Phase 3
Completed NCT01430871 - Effects of Serotonin Excess on Bone in Carcinoid Syndrome N/A
Completed NCT02026063 - Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Phase 3
Terminated NCT01018953 - Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Phase 2
Terminated NCT04140409 - Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation Phase 4